ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag coronary heart disease neuroscience disease medicine

Coronary Disease
The Scientist Staff | Jun 7, 1998 | 4 min read
POSITIVE REDUCTION: Frank M. Sacks (left) of Brigham and Women's Hospital and Harvard University led a study that demonstrated that lowering cholesterol in patients from average to low levels significantly reduced the number of recurrent coronary events. The research team also included Lemuel A. Moye (right) of the University of Texas School of Public Health in Houston. F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, T.G. Cole, L. Brown, J.W. Warnica, J.M.O. Arnold, C.C. W
A clinician (off screen) wearing blue gloves presses a diapered infant’s heel against a paper card to collect blood samples.
Did Researchers Really Uncover the Cause of SIDS?
Dan Robitzski | May 18, 2022 | 10 min read
An interesting but preliminary biomarker study’s reception illustrates the challenges of conducting and communicating nuanced research in the era of social media.
Heart Disease
The Scientist Staff | Sep 26, 1999 | 3 min read
Edited by: Eugene Russo P.M. Ridker, M. Cushman, M.J. Stampfer, R.P. Tracy, C.H. Hennekens, "Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men," New England Journal of Medicine, 336:973-9, April 3, 1997. (Cited in more than 250 papers since publication) Comments by Paul M. Ridker, associate professor of medicine, Brigham and Women's Hospital, Boston Physicians typically check patients for signs of cardiovascular disease, or atherosclerosis, by measuring
Haydeh Payami is wearing a purple dress and an orange and pink scarf and standing in front of a whiteboard.
A Microbial Link to Parkinson’s Disease
Mariella Bodemeier Loayza Careaga, PhD | Dec 4, 2023 | 6 min read
Haydeh Payami helped uncover the genetic basis of Parkinson’s disease. Now, she hopes to find new ways to treat the disease by studying the gut microbiome.
Mutation Tied to Reduced Heart Disease
Kerry Grens | Jun 20, 2014 | 2 min read
Genetic variants that cripple a triglyceride-producing protein are linked with a lower risk of heart attack and stroke.
FDA Approves Oral Drug for Fabry Disease
Ashley Yeager | Aug 13, 2018 | 2 min read
The medicine increases the activity of a deficient enzyme in certain patients with the condition.
PCSK9 Drug Reduces Heart Disease Risk
Diana Kwon | Mar 21, 2017 | 2 min read
A cholesterol-lowering drug significantly cut the risk of heart attack and stroke in a recent study. But is it worth the steep cost?
pharmacology medicine parkinson's disease dopamine l-dopa levodopa Hornykiewicz obituary
Oleh Hornykiewicz, Who Pioneered Treatment for Parkinson’s, Dies
Amanda Heidt | Jun 18, 2020 | 3 min read
The University of Toronto and University of Vienna pharmacologist developed L-dopa, a precursor to dopamine that remains the most widely used therapy for Parkinson’s disease.
Trans Fats Linked to Heart Disease, Early Death
Kerry Grens | Aug 14, 2015 | 2 min read
The consumption of trans fats is tied to a higher chance of disease and dying sooner, according to a systematic review.
A blood test tube with the label ‘cfDNA Screening–Test’, held in a hand wearing blue gloves.
The Basics and Applications of Cell-Free DNA 
Rebecca Roberts, PhD | Nov 8, 2023 | 5 min read
Found circulating in peripheral blood, scientists use cell-free DNA (cfDNA) to assess genetic abnormalities, infections, cancer, transplant rejection, and cardiovascular disease.

Run a Search

ADVERTISEMENT